Coverage clusters in regulation, which accounts for 4 of those 5, with the remainder spread across 1 other category. Against the same-window beat baseline of 44% negative, this entity's 0% share is less negative. Across a 158-day span, the pace is roughly 0.2 stories per week. The busiest single day carried 2.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Nasdaq
Coverage clusters in regulation, which accounts for 4 of those 5, with the remainder spread across 1 other category. Against the same-window beat baseline of 44% negative, this entity's 0% share is less negative. Across a 158-day span, the pace is roughly 0.2 stories per week. The busiest single day carried 2. Blockchain is the most frequent co-covered peer, appearing in 2 of the 5 tracked stories. Their average consequence score of 6.6 runs above the beat's 6.5 for that window. Source depth averages 3.6 original sources per story, versus 3.4 across the same-window beat baseline. Nasdaq appears in 5 tracked Legal stories published from February 24, 2026 through July 31, 2026.
Stories tracked
5
Per week
0.2
Negative
0%
Sources per story
3.6
Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 1719 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Nasdaq. Shared-story counts are live from our verified record — not editorial picks.
Expected launch of a pilot program for select S&P 500 stocks on the new DLT infrastructure.
Compliance Demands & Legal Pursuit Announced
Company announces it will submit compliance demands to clearinghouses and prime brokers ahead of mandatory legal action for FTDs and volume anomalies, and unveils a forensic audit strategy.
Retention of Christian Attar
DBGI retained the law firm Christian Attar to investigate potential naked short selling and market manipulation of its common shares.
SEC Approval
The SEC grants Nasdaq the authority to move public equity settlement to a blockchain ledger.
ICE Announcement
Intercontinental Exchange reveals development of a platform for on-chain settlement of securities.
Initial Filing
Nasdaq files a proposal with the SEC to amend rules for tokenized trading on its main market.
T+1 Implementation
U.S. markets transition to a one-day settlement cycle to reduce systemic risk.
Linq Launch
Nasdaq successfully completes its first private share trade using blockchain technology.
Indian experts argue Fidelity's 15-day lock on SpaceX IPO shares violates investor rights, while SEBI's regulatory framework would never permit such a restriction. A legal analysis of broker-imposed trading limits and investor protection.
Digital Brands Group escalates its fight against alleged naked short selling by demanding compliance from clearinghouses and threatening litigation, backed by a forensic audit and the retention of boutique law firm Christian Attar. The move signals a rare issuer-led enforcement initiative targeting cross-border settlement anomalies and FTDs, with significant implications for securities regulation and civil liability theories.
The SEC has officially approved Nasdaq's proposal to integrate blockchain technology into its core trading infrastructure, marking a historic shift toward real-time settlement. This move transitions the traditional T+1 settlement cycle toward an 'atomic' model, potentially saving billions in collateral requirements and reducing systemic risk.
The U.S. Securities and Exchange Commission (SEC) has approved a landmark proposal by Nasdaq to allow certain stocks and exchange-traded products to be traded and settled in tokenized form. This decision marks a significant integration of blockchain technology into mainstream equity markets, initially targeting high-volume securities within the Russell 1000 Index and major benchmark ETFs.
Corcept Therapeutics (NASDAQ: CORT) is the target of a class action lawsuit alleging securities fraud between October 2024 and December 2025. The Rosen Law Firm is leading the litigation, which centers on claims that the company misled investors regarding its business operations and regulatory compliance. This legal challenge marks a critical period of scrutiny for the pharmaceutical firm's corporate governance and public disclosure practices.